Upload
brittney-andrews
View
217
Download
2
Embed Size (px)
Citation preview
Alzheimer’s Disease Neuroimaging Initiative
STEERING COMMITTEE
Michael W. Weiner
10TH YEAR ANNIVERSARY
• Discussions about ADNI began in 2001• ADNI funded in 2004• We still have 2 ½ years of ADNI2• Encouraged to submit an ADNI2
THE BIG PICTURE
• Overall, ADNI is doing very well– We are more than half-way through ADNI2
• We have overenrolled• Drop outs are low• Many publications: widespread data sharing• Clinical trials use ADNI results and methods• High interest in a renewal: ADNI3
– Very high interest in longitudianal tau PET!– High interest in studying the “earliest stages”
SPECIFIC ACCOMPLISHMENTS
• First and largest multisite study: amyloid phenotyping:– PIB– Florbetapir– CSF amyloid
• These measurements, together with clinical, cognitive, MRI, FDG PET, genetic make for a huge resource
• Clifford Jack’s “model” of progression
Disease progression
Seminal paper by Jack et al (2010) proposed a model for disease progression that formed the basis of many subsequent studies.
500…
or 15.3 inches (38cm), double-sided.
Over 3200 publications mention “Alzheimer’s Disease Neuroimaging Initiative” (Google Scholar)
Plus > 300 submitted
PROBLEMS
• Very large, complex project, difficult to understand all activities
• Projected budget deficit:– Plan is to eliminate: – ADs, Control and SMC alternate years, MRIs
of MCI on alternate years, all FDG PET– Formal notification to sites coming soon
• Delay in data upload from sites: – Major Problem: difficult to track drop outs
TAU PET
• Very promising because tau– Correlates with symptoms much better than
amyloid (based on autopsy)– Is a potential “surrogate outcome” for clinical
trials because• Autopsy has shown that tangle accumulation closely
correlates with neurodegeneration• Thus slowing of tau tangle accumulation may be a
valid surrogate for slowing of disease progression• Tau PET may have higher power than cognition
GRANT SUBMISSIONS FOR TAU PET (T807)
• Department of Defense: – Multisite tau PET add-on to DOD ADNI:
Effects of TBI and PTSD on AD in Vietnam Veterans. Includes some ADNI subjects
• NIA: Competitive supplement to ADNI2:– Longitudinal multisite tau PET: all 5 subject
groups. Will be reviewed in June 2014
• AVID has offered T807 without cost for these grants
WHAT IS NEXT
• ADNI 3 submission could be as early as June 2015, depending on advise from NIA– Overall goal: Validation of biomarkers for AD trials
• A focus will be on longitudinal tau PET• Strong interest in early development of AD
– Possibly enroll younger subjects– Consider less emphasis on demented subjects
• We need input from Site PIs, NIA, Pharma, Foundations, and others to plan ADNI3
OTHER HIGHLIGHTS
• Emerging longitudinal data of ADNI2• Mass Spectroscopy analysis of CSF amyloid
– May reduce the problems of quantification
• Whole genome sequencing• Multimodal MRI
COMPARISON OF ASL-PERFUSION MRI, FDG PET, sMRI
Philp Insel, Duygu Tosun, Niklas Mattsson, Norbert Schuff, Michael Weiner
VA Medical Center, UCSF
GOAL AND METHODS
• To compare the sensitivity of ASL-MRI, FDG PET, and sMRI to detect changes due to AD at different disease stages
• All comparisons are performed against amyloid negative normal controls
• Amyloid positive subjects: – Controls, EMCI, LMCI, AD
• Used both CSF and Florbetapir for phenotyping
[unpublished data]
FDG
CBF
STR
Aβ+ Early MCI Aβ+ MCI Aβ+ ADAβ+ CN
Aβ+ CN vs Aβ- CN Aβ+ eMCI vs Aβ- CN Aβ+ MCI vs Aβ- CN Aβ+ AD vs Aβ- CN
ACC SENS SPEC ACC SENS SPEC ACC SENS SPEC ACC SENS SPEC
FDG 0.84±0.07
0.58±0.26
0.95±0.10
0.74±0.04
0.66±0.11
0.82±0.07
0.70±0.09
0.42±0.17
0.89±0.15
0.75±0.09
0.66±0.10
0.82±0.15
CBF 0.81± 0.12
0.66±0.16
0.88±0.10
0.72±0.07
0.68±0.13
0.79±0.11
0.72±0.09
0.49±0.14
0.87±0.12
0.69±0.09
0.61±0.22
0.63±0.10
STR 0.95±0.05
0.92±0.08
0.94±0.05
0.92±0.06
0.92±0.08
0.92±0.11
0.86±0.04
0.82±0.10
0.89±0.10
0.94±0.02
0.94±0.06
0.93±0.04
VOXEL BASED COMPARISONS: USED FLORBETAPIR
NL+ vs. NL- : All Modalities
EMCI+ vs. NL- : All Modalities
LMCI+ vs. NL- : All Modalities
AD+ vs. NL- : All Modalities
ASL: All DX
FDG: All DX
Volume: All DX
Headings
SUMMARY AND CONCLUSION
• Cerebral blood flow, measured by ASL MRI, favorably compares with FDG PET and sMRI– Especially in earlest stages
• Changes in CBF occur in same/different regions than FDG PET, the techniques are complementary
• ASL appears particularly useful to detect early changes in controls and EMCI
• 3D ASL sequences are expected to provide improved results
MANY THANKS
• NIA for strong support• Industry Partners, Foundations, and FNIH• Site PIs, study coordinators• ADCS staff• Subjects and their families